$0.00
Register for Meetings
“In The News” & “Cardiovascular Marketplace” Content Access
Listen to Podcasts
Watch On-Demand Content
CardioTube Access
Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference
Access Recorded Interviews
Download PPT Slide Decks
Already have an account? Login Now
$650 Annually
Complimentary subscription to electronic version of the CRM Journal
Access to CRT Meeting Registration Discounts
CRT Premium Content, including on-demand videos and presentation downloads
Judy George, Contributing Writer, MedPage Today, October 03, 2017
Low-dose tissue plasminogen activator (tPA, alteplase) showed no clear benefits over standard dosing among key subgroups of acute ischemic stroke patients, a secondary analysis of the ENCHANTED trial found.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details